HOMAYOUN SIMAN: Open Payments
NPI 1477971125 · PALM DESERT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$210 in 10 payments from 7 companies in 2025. Trend: 2023 $727 · 2024 $419 · 2025 $210
Food & beverage: $210
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Amgen Inc. | 2 | $41 |
| PFIZER INC. | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
Products named: TRELEGY ELLIPTA, MOUNJARO, ELIQUIS, REPATHA, EVENITY, Wegovy, FARXIGA, KISUNLA.
Industry payments across CA — which companies pay providers there.
